



RPG LIFE SCIENCES LIMITED
Unit No. 208-213, B Wing,
Bezzola Complex,
Sion-Trombay Road, Chembur,
Mumbai 400071, India
Tel: +91-22-25292152-55
Fax: +91-22-25297423

October 17, 2022

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of Press Release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022.

Kindly take the above on record.

Thanking you,

Yours Sincerely,

For RPG Life Sciences Limited

RAJESH RAMESH SHIRAMBEKAR
Digitally signed by RAJESH
RAMESH SHIRAMBEKAR
Date: 2022.10.17 19:19:24
+05'30'

Rajesh Shirambekar
Head – Legal & Company Secretary

Encl.: as above



**Q2 FY23 Revenue from operations grew by 20% Y-o-Y and 5% Q-o-Q.
PBT grew by 21% Y-o-Y and 8% Q-o-Q.**

Mumbai, 17 October, 2022: RPG Life Sciences Limited has announced its financial results for the second quarter and half year ended September 30, 2022.

	Y-o-Y Revenue from operations	Y-o-Y PBT
Q2 FY23 Highlights	Rs 134.79 crores – up from Rs 112.65 crores	Rs 27.01 crores – up from Rs 22.35 crores
H1 FY23 Highlights	Rs 263.72 crores – up from Rs 220.78 crores	Rs 52.13 crores – up from Rs 41.62 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 21% Y-o-Y and by 8% Q-o-Q for Q2 FY23, maintaining the upward trajectory in EBITDA margins, which improved from 22.5% to 23.0% Q-o-Q. Revenue from operations at Rs 134.79 crores registered a growth of 20% Y-o-Y and a growth of 5% Q-o-Q for Q2 FY23. For H1 FY23 too, the company posted a jump in PBT by 25% Y-o-Y and recorded EBITDA margin expansion from 22.6% to 22.8% Y-o-Y. Revenue from operations at Rs 263.72 crores registered a growth of 19% Y-o-Y for H1 FY23.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q2 FY23, the overall performance of the Company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 20% and 21% respectively Y-o-Y. EBITDA margin retained its upward trajectory growing from 22.5% to 23.0% Q-o-Q.

Domestic Formulations business has recorded a robust growth both in value and volumes - significantly and consistently ahead of market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has shown a robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations and eye on sales hygiene is helping us to consistently improve our margins. We are on course to implement our Transformation Agenda to achieve our strategic goals.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US\$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact:

Sumeet Chatterjee
Senior Vice President – Corporate Brand and Group Communications
+91 9820340650 | sumeet@rpg.in



An **RPG** Company